stockrowSotera Health Company
SHC Healthcare Diagnostics & Research
Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Revenue
- +4.36%
- EPS
- +20.1%
- Free cash flow
- +65.0%
- Total debt
- +0.14%
Quarter to September 2026, against a year earlier
Follow SHC
Alert me
Sotera Health Company (SHC) Total debt
Sotera Health Company's total debt at the end of fiscal 2025 was $2.2B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $2.2B. Over the past ten years it has ranged from $1.8B (fiscal 2021) to $2.8B (fiscal 2019); the current reading is higher than 50% of that period. Sotera Health Company ranks 11th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $2.2B | (3.61%) |
| FY2024 | $2.3B | 3.10% |
| FY2023 | $2.2B | 12.36% |
| FY2022 | $2.0B | 11.52% |
| FY2021 | $1.8B | (4.08%) |
| FY2020 | $1.9B | (34.29%) |
| FY2019 | $2.8B | 27.30% |
| FY2018 | $2.2B | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $2.2B | 0.43% |
| Jun 2026 | $2.2B | (0.02%) |
| Mar 2026 | $2.2B | (0.14%) |
| Dec 2025 | $2.2B | (0.13%) |
| 23 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| SHC Sotera Health Company | $2.2B |
| QGEN QIAGEN N.V. compare | $1.6B |
| RDNT RadNet, Inc. compare | $1.3B |
| NEO NeoGenomics, Inc. compare | $378.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $334.9M |
| BLLN BillionToOne, Inc. compare | $89.1M |
| CDNA CareDx, Inc. compare | $35.2M |
| VCYT Veracyte, Inc. compare | $14.0M |
| GRAL GRAIL, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on SHC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement